ストックスクリーナーアプリを入手
510.04
4.64%
-24.82
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MDGL) 2026-05-09 - Seeking Alpha
Madrigal Pharmaceuticals (MDGL) Quarterly Loss Of US$94 Million Tests Bullish Margin Turnaround Narrative - Sahm
MDGL Maintained by Canaccord Genuity -- Price Target Lowered to $578 - GuruFocus
Madrigal (MDGL) Reports Strong Q1 Revenue and Positive Market Ou - GuruFocus
MDGL Maintains Rating by Evercore ISI Group -- Price Target Lowe - GuruFocus
47 new Madrigal hires get stock awards; options priced at $513.72 - Stock Titan
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript - Insider Monkey
Madrigal Q1 2026 slides: blockbuster Rezdiffra tops $1.1B in sales - Investing.com Australia
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Madrigal: Q1 Earnings Snapshot - theheraldreview.com
MSN Money - MSN
Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027 - MSN
Madrigal Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Madrigal Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Madrigal Pharmaceuticals Q1 2026 Financial Results and Forward-Looking Statements – Rezdiffra Commercialization and Regulatory Updates - Minichart
Madrigal Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals Reports Blockbuster Rezdiffra Sales and Pipeline Expansion in Q1 2026 Financial Results - Minichart
Madrigal Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline Expansion - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3 - Pharmaceutical Executive
Earnings call transcript: Madrigal Pharmaceuticals Q1 2026 surprises with earnings beat - Investing.com
Full Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call - Benzinga
Madrigal Pharmaceuticals (NASDAQ: MDGL) grows Rezdiffra revenue but remains loss-making - Stock Titan
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Dip Despite Q1 2026 Earnings Beat and 127% Rezdiffra Revenue Growth - ChartMill
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Q1 2026 Madrigal Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
MADRIGAL PHARMACEUTICALS ($MDGL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, Vs. FactSet Est of $4.23 Loss - Moomoo
Madrigal Pharmaceuticals, Inc. announced that its drug interaction study for Ervogastat/Resmetirom is progressing steadily and is expected to officially launch in the fourth quarter of 2026. - Bitget
42,250 patients use Rezdiffra as Madrigal adds MASH gene drug - Stock Titan
Madrigal Pharmaceuticals, Inc. Announces Board Changes, Effective April 22, 2026 - marketscreener.com
Rezdiffra powers Madrigal Pharmaceuticals (NASDAQ: MDGL) to 127% Q1 revenue growth - Stock Titan
BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million - TradingView
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - Yahoo Finance
Madrigal doubles down on MASH with second licensing deal - BioXconomy
Madrigal Expands MASH Franchise With Precision RNAi License For ARO PNPLA3 - simplywall.st
Should Madrigal’s ARO-PNPLA3 License Deal Reshape the MASH Strategy for Madrigal Pharmaceuticals (MDGL) Investors? - Yahoo Finance
Madrigal Pharmaceuticals Q1 2026 earnings preview - MSN
Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH - MedCity News
Madrigal earnings on deck: Can Rezdiffra sustain blockbuster pace? - Investing.com
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead - marketscreener.com
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com South Africa
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline - The Manila Times
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Madrigal Pharmaceuticals (MDGL) Stock Analysis: Exploring a 31% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
(MDGL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Madrigal upgraded at Cantor on Rezdiffra launch - MSN
11.97%
3.48%
大文字化:
|
ボリューム (24 時間):